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Ethics The hESC line KCL033 is derived under license from the UK
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. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
license numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics Com-
mittee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the ex-
periments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.
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Embryo thawed Jul 11, 2011
UK stem cell bank deposit approval Mar 08, 2012
Reference: SCSC12-54
Sex Female 46, XX
Grade Clinical
Disease status Healthy/Unaffected
Karyotype (aCGH) No copy number changes detected.
SNP array Gain in regions 5p14.3 and 12p11.21
(Canham et al., 2015)
DNA ﬁngerprint Allele sizes (in bp) of 16 microsatellite
markers speciﬁc for chromosomes 13,
18 and 21 (Jacquet et al., 2013)
HLA typing HLA-A 11,29; B 44,51; Bw 4; C 04,16;
DRB1 04,07; DRB4 01; DQB1 02,03
(Jacquet et al., 2013; Canham et al.,
2015)
Viability testing Pass
Mycoplasma Negative
Sterility Pass
Pluripotent markers
(immunostaining)
(Fig. 1)
NANOG, OCT4, TRA-1-60, TRA-1-81
Three germ layers differentiation
in vitro (immunostaining)
(Fig. 2)
Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class
III)
Mesoderm: ACTA2 (actin, alpha 2,
smooth muscle)
Sibling lines available KCL032, KCL034
Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining
(Oct. 4, Nanog, TRA-1-60, TRA-1-81). Scale bar, 50 μm.We generated KCL033 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed a novel 2.4 Mb gain on chromo-
some 5p14.3 and a gain on chromosome 12p11.21, which was also
found in KCL040.
The gain on chromosome 5p14.3 containing a single gene, CDH18
(Cadherin-18), was also present in one of two sibling cell lines,
KCL032, but not in KCL034, a third sibling. A duplication of this size
has not been reported to date, but its presence in two sibling hESC
lines strongly suggests that it was inherited from one of the parents
rather than by acquisition during hESC derivation and culture
(Canham et al., 2015). The 2498.8 bp gain starts at bp 19086546
and ends at bp 21585311 as referred to Human Genome Build 38.
The gain on chromosome 12p11.21 contains no genes and it has
been also reported in at least 14 submissions at Database of Genomic
Variants (DGV; http://dgv.tcag.ca), which has collected structural
variations in more than 14,000 healthy individuals from worldwide
population (MacDonald et al., 2014). Estimated frequency in the
human population is 4.70% (Canham et al., 2015).
Validation for sterility and speciﬁc and non-speciﬁc human patho-
gens (Devito et al., 2014) conformed that the cells in the Master Bank
were sterile, mycoplasma-free, and negative for Treponema pallidum,
chlamydia, Neisseria gonorrhoeae, human immunodeﬁciency virus-1 and 2 (HIV-1 and -2), human T-lymphotropic virus types-1 and 2
(HTLV-1 and 2), hepatitis A, B and C (HAV, HBV and HCV), human
herpes simplex virus HHV-4 (Epstein–Barr virus, EBV), -6, -7, and -8,
human cytomegalovirus (hCMV), human parvovirus B19, SV40, JCV,
BKV, enterovirus, HAV, HCV, nonspeciﬁc viral and other adventitious
contaminants.
We also generated research grade of KCL033 line that is adapted to
feeder-free conditions.
Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to re-
search embryos that were stored for 5 or 10 years. They mail signed
consent back to us and that might be months after the PIS and consent
were mailed to them. If in meantime new versions of PIS/consent are
implemented, we do not send these to the patients or ask them to re-
sign; the whole process is done with the version that was given them
initially. The PIS/consent documents (FRO-V.6) were created on Dec.
18, 2008. HFEA Code of Practice that was in effect at the time of docu-
ment creation: Edition 7 — R.4 (http://www.hfea.gov.uk/2999.html).
The donor couple signed the consent on May 26, 2009. HFEA Code of
Practice that was in effect at the time of donor signature: Edition 7 —
R.4. HFEA Code of Practice Edition 7 — R.4 was in effect: 02 Oct. 2008–
30 Sep. 2009.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in detail (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically from the outgrowth (Ilic et al., 2007; Ilic et al., 2010). hES col-
onies were expanded and cryopreserved at the third passage.
Fig. 2. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).Pluripotency markers
Pluripotency was assessed with immunostaining for pluripotency
markers as described (Ilic et al., 2012; Stephenson et al., 2012).Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Petrova et al., 2014; Stephenson
et al., 2012).Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.Array comparative genomic hybridization (aCGH)
aCGH was performed as described in detail (Ilic et al., 2012).Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in detail (Canham et al.,
2015).HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al.,
2013). HLA typing was also performed independently by other group
(Canham et al., 2015).Validation for sterility and speciﬁc and non-speciﬁc human pathogens
Validation for sterility and speciﬁc and non-speciﬁc human path-
ogenswas performed as described (Devito et al., 2014). All validation
studies were conducted by SGS Vitrology (Glasgow, U.K., http://
www.sgs.com), in compliance with the principles of GMP as set out
in Directive 2003/94/EC for medicinal products for human use
(Directive 2003/94/EC, 2003) and 91/412/EEC for veterinary medic-
inal products (Directive 91/412/EEC, 1991).
Sterility testing was performed in accordance with the current re-
quirements of the European Pharmacopoeia, Section 2.6.1 Sterility,
U.S. Pharmacopeia, 71. Sterility Tests, and International Conference on
Harmonisation Topic Q5D guidelines.
Mycoplasma testing was performed in accordance with the cur-
rent requirements of the European Pharmacopoeia, Section 2.6.7,
Mycoplasmas.
All PCR-based assays used were compliant with the current edition
of the European Pharmacopoeia, 2.6.21, Nucleic Acid Ampliﬁcation
Techniques.
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